Foresight 4 VCT plc
Interim Management Statement for the Quarter Ended 30 June 2014
Foresight 4 VCT plc presents its interim management statement for the quarter ended 30 June 2014. This constitutes the company's first interim management statement for the financial year ending 31 March 2015, as required by the UK Listing Authority's Disclosure and Transparency Rule 4.3.
At 30 June 2014, there were 38,569,414 Ordinary shares in issue. During the three months ended 30 June 2014 no shares were allotted or bought back.
At 30 June 2014, there were 18,680,907 C shares in issue. During the three months ended 30 June 2014 no shares were allotted or bought back.
Net assets of the Ordinary Shares fund at 30 June 2014 comprised the following:
£'000 | % of Net Assets | ||
Unquoted Investments at fair value as determined by the Directors | 31,719 | 94.9% | |
Quoted investments at bid price | 184 | 0.5% | |
Total venture capital investments | 31,903 | 95.4% | |
Net Current Assets | 1,539 | 4.6% | |
Net Assets | 33,442 | 100.0% |
Net assets of the C Shares fund at 30 June 2014 comprised the following:
£'000 | % of Net Assets | ||
Unquoted Investments at fair value as determined by the Directors | 11,668 | 82.7% | |
Quoted investments at bid price | - | - | |
Total venture capital investments | 11,668 | 82.7% | |
Net Current Assets | 2,435 | 17.3% | |
Net Assets | 14,103 | 100.0% |
Quoted investments are stated at bid price as at 30 June 2014. Unquoted investments are stated at fair value as at 30 June 2014 as determined by the Directors.
During the three months ended 30 June 2014 the following significant investment transactions took place (all companies unquoted except where otherwise indicated):
Ordinary Shares Portfolio
New and follow-on investments:
Name of Company | Business Activity | Type of addition | Amount Invested £'000 |
AlwaysON Group | Data storage, data protection and Microsoft solutions specialist | Working capital | 130 |
Biofortuna | Molecular diagnostics business with expertise in enzyme stabilisation, effectively hi-tech freeze drying | Growth capital | 51 |
Investment disposals:
Name of Company | Business Activity | Carrying value £'000 | Proceeds £'000 |
Amberfin | Specialist broadcast software and services | 116 | 54 |
C Shares Portfolio
Follow-on investments:
Name of Company | Business Activity | Type of addition | Amount Invested £'000 |
Biofortuna | Molecular diagnostics business with expertise in enzyme stabilisation, effectively hi-tech freeze drying | Growth capital | 51 |
Investment disposals:
There were no disposals in the period.
For further information please contact:
Gary Fraser, Foresight Group: 0203 667 8109